This clinical trial aims to help people who have had a lung transplant. The study will have 350 participants, and they're divided into two groups: one gets the drug Tocilizumab (TCZ) along with usual medications, and the other group gets a placebo (a harmless substance) with the usual medications. The main goal is to see if adding TCZ helps better than just the usual treatment in preventing problems like Chronic Lung Allograft Dysfunction (CLAD), the need for another transplant, or death.

Key Points:

• Study has 6 doses over 20 weeks.
• Total of 350 participants are needed.
• Participants may receive compensation for involvement.

To be part of this study, you must have had a single or double lung transplant and meet specific health requirements. You cannot join if you have certain health conditions, like a history of severe allergies or specific infections. Participants should be willing to follow the study’s guidelines, including using effective birth control if applicable.